New Life for a Failed Drug Class

An oral CETP inhibitor — both alone and combined with ezetimibe — significantly reduced LDL-C in high-risk patients already on cholesterol-lowering therapies.

Two recent manufacturer-funded, randomized, placebo-controlled trials evaluated the non–FDA-approved cholesteryl ester transfer protein (CETP) inhibitor obicetrapib for lowering low-density lipoprotein cholesterol (LDL-C) in patients at high risk for cardiovascular disease.

The first trial tested oral obicetrapib 10 mg once daily in 2500 patients with heterozygous familial hypercholesterolemia or a history of atherosclerotic cardiovascular disease (ASCVD) who had LDL-C levels ≥100 mg/dL or non–high-density lipoprotein cholesterol (HDL-C) levels ≥130 mg/dL despite maximum tolerated lipid-lowering therapy. At 84 days, LDL-C levels decreased significantly more with obicetrapib than with placebo (mean change from baseline, −30% vs. +3%) at day 8…

Reviewing Author

Karol E. Watson, MD, PhD, FACC

Disclosures

Consultant/Advisory BoardBoehringer Ingelheim; Amgen; Novartis; Lilly; Amarin

Speaker’s BureauBoehringer Ingelheim

Grant/Research SupportNIH

Editorial BoardsCirculation (Associate Editor)